Compare BLX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | ADPT |
|---|---|---|
| Founded | 1977 | 2009 |
| Country | Panama | United States |
| Employees | 372 | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 1997 | 2019 |
| Metric | BLX | ADPT |
|---|---|---|
| Price | $53.77 | $12.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $17.78 |
| AVG Volume (30 Days) | 119.3K | ★ 1.5M |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $18.36 | $3.98 |
| Revenue Next Year | $9.95 | $22.72 |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $38.41 | $8.50 |
| 52 Week High | $57.79 | $20.76 |
| Indicator | BLX | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 39.36 |
| Support Level | $52.31 | $12.22 |
| Resistance Level | $55.30 | $13.45 |
| Average True Range (ATR) | 1.34 | 0.77 |
| MACD | -0.25 | -0.14 |
| Stochastic Oscillator | 51.65 | 10.52 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.